ITAT directs re-evaluation of R&D and professional fees claims for consistency with prior rulings.

The ITAT partly allowed the appeal, directing the AO to re-evaluate the R&D expenditure claim and professional fees based on the provided guidelines and previous decisions. The order emphasized consistency with earlier favorable rulings in similar cases for the assessee.

---

---

Issues Involved:
1. Disallowance of R&D expenditure under section 35(2AB).
2. Disallowance of professional fees as capital expenditure.

Issue-wise Detailed Analysis:

1. Disallowance of R&D Expenditure under Section 35(2AB):

The assessee filed its return of income declaring Rs. 4,20,890/-. During the scrutiny, the Assessing Officer (AO) observed that the assessee claimed R&D expenditure of Rs. 5,03,34,595/- under section 35(2AB) of the Income-tax Act, 1961, while the Department of Scientific and Industrial Research (DSIR) approved only Rs. 3,41,02,000/-. The AO disallowed the excess claim of Rs. 1,62,32,595/-.

The assessee argued that the sale realization from R&D work should not be reduced from the revenue expenditure, citing the Karnataka High Court decision in CIT v. Micro Lab Ltd. and a similar ITAT Mumbai decision in ACIT v. Wochardt Ltd. The CIT(A) upheld the AO's disallowance, leading the assessee to appeal to the ITAT.

The ITAT reviewed the Karnataka High Court's decision, which held that sales realization from products emanating from R&D work should not be offset against R&D expenditure, as such sales are reflected as business receipts. The ITAT directed the AO to exclude only those incomes which are in the category of dossier, not the product/assets and contract income, and allowed the ground for statistical purposes.

2. Disallowance of Professional Fees as Capital Expenditure:

The AO disallowed professional fees totaling Rs. 67,40,685/- as capital expenditure. The assessee argued that similar disallowances in previous years were deleted by the CIT(A) and ITAT, particularly for payments to Dr. May Pharma and Ventures Corp Consultants, which were allowed by ITAT for A.Y. 2008-09 and A.Y. 2009-10.

The CIT(A) partly allowed the appeal, sustaining the disallowance for payments to Asian Patent Bureau, John A. Mccrerie, and Dr. Dilip Snavordekar, considering them capital in nature as they conferred enduring benefits to the assessee.

The ITAT reviewed the decisions in earlier assessment years and followed the precedent. It allowed the disallowance for Asian Patent Bureau and Dr. Dilip Snavordekar based on previous favorable ITAT decisions in assessee's own case. For John A. Mccrerie, the ITAT remitted the issue back to the AO to verify the genuineness of the claim and allow it if it falls within the category of other consultancy charges allowed in previous grounds.

Conclusion:

The ITAT partly allowed the appeal, directing the AO to re-evaluate the R&D expenditure claim and professional fees based on the provided guidelines and previous decisions. The order emphasized consistency with earlier favorable rulings in similar cases for the assessee.

---